Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer
Prostate cancer (PCa) is the second most common cancer in men worldwide and the fifth leading cause of death by cancer. The overexpression of TCTP protein plays an important role in castration resistance. Over the last decade, antisense technology has emerged as a rising strategy in oncology. Using...
Main Authors: | Guillaume Sicard, Clément Paris, Sarah Giacometti, Anne Rodallec, Joseph Ciccolini, Palma Rocchi, Raphaëlle Fanciullino |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/12/1166 |
Similar Items
-
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
by: Maria Gagliardi, et al.
Published: (2021-04-01) -
Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas
by: Raghav Gupta, et al.
Published: (2023-05-01) -
Quantitative fluorescence imaging of antisense oligonucleotide mediated knockdown
by: Chan, Nicholas Zhen Woon
Published: (2024) -
In-silico study of antisense oligonucleotide antibiotics
by: Erica S. Chen, et al.
Published: (2023-11-01) -
Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
by: Maria Gagliardi, et al.
Published: (2022-01-01)